Previous Article | Next Article 
Molecular and Cellular Biology, November 2000, p. 8420-8431, Vol. 20, No. 22
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
p53 Binds Selectively to the 5' Untranslated Region of
cdk4, an RNA Element Necessary and Sufficient for
Transforming Growth Factor
- and p53-Mediated Translational
Inhibition of cdk4
Susan J.
Miller,1,
Tuangporn
Suthiphongchai,1,
Gerard P.
Zambetti,2 and
Mark E.
Ewen1,*
Dana-Farber Cancer Institute and Harvard
Medical School, Boston, Massachusetts 02115,1
and Department of Biochemistry, St. Jude Children's
Research Hospital, Memphis, Tennessee 381052
Received 15 June 2000/Returned for modification 22 August
2000/Accepted 1 September 2000
 |
ABSTRACT |
One consequence of transforming growth factor
(TGF-
)
treatment is inhibition of Cdk4 synthesis, and this is dependent on p53. Here, we show that the 5' untranslated region (UTR) of the cdk4 mRNA is both necessary and sufficient
for wild-type p53-dependent TGF-
-regulated translational inhibition
of cdk4. Wild-type p53 bound selectively to the 5' UTR of
the cdk4 mRNA and inhibited translation of RNAs that
contain this region. RNA binding and translational control
are two genetically separable functions of p53, as are specific and
nonspecific RNA binding. Moreover, transactivation-defective mutants of
p53 retain the ability to regulate cdk4 translation. Our
findings suggest that p53 functions as a regulator of translation in
response to TGF-
in vivo.
 |
INTRODUCTION |
Progression through the
G1 phase of the cell cycle is regulated in part by Cdk4 and
its regulatory subunits, the D-type cyclins, as well as Cdk2 and cyclin
E. Cdk4 and Cdk2 cooperate to functionally inactivate the
retinoblastoma protein, pRb, thereby committing the cell to enter S
phase. Extracellular signals influence a number of signal transduction
pathways that converge on the regulation of Cdk4 activity. Transforming
growth factor beta (TGF-
) is a multifunctional cytokine that has
been shown to inhibit cellular proliferation by blocking progression
through G1 by preventing the phosphorylation of pRb. Work
in several systems indicates that Cdk4 is the primary target of TGF-
action. This cytokine has been shown to induce the Cdk4-specific
inhibitors p15INK4b and p21CIP1, leading to the
inactivation of D-type cyclin-dependent kinase activity (2, 8,
19). Treatment with TGF-
leading to decreased expression of
the Cdc25A phosphatase and, consequently, increased tyrosine
phosphorylation at inhibitory sites resulting in inactive Cdk4 has also
been documented (9). In addition, it has been demonstrated
that TGF-
treatment leads to the inhibition of Cdk4 synthesis
(4). For a given cell system, these mechanisms are not
necessarily mutually exclusive, suggesting that redundant events
leading to the efficient inactivation of Cdk4 exist. The importance of
inhibiting Cdk4 activity for an effective TGF-
antiproliferative
response is underscored by the observation that enforced expression of
Cdk4, but not Cdk2, renders cells resistant to TGF-
-induced growth
arrest (4).
Previously we demonstrated that in Mv1Lu mink lung epithelial cells,
which have one of the best characterized antimitogenic responses to
TGF-
, downregulation of Cdk4 following TGF-
treatment occurs at
the level of translation (5). The ability of the cytokine to
affect cdk4 translation is dependent on functional wild-type
p53. This was evidenced by the observation that expression of a
dominant-negative mutant of p53 prevented inhibition of cdk4 synthesis following TGF-
treatment. A possible explanation for these
phenomena was provided by the demonstration that in transiently transfected cells, wild-type, but not mutant, p53 could inhibit the
translation of cdk4. Moreover, the ability of p53 to inhibit Cdk4 synthesis in this system was shown to be dependent on the 5'
untranslated region (UTR) of cdk4 (5).
The previous work left a number of important questions unanswered
regarding TGF-
-mediated inhibition of Cdk4 synthesis. Here, we have
addressed these issues. We have asked whether TGF-
-mediated inhibition of Cdk4 synthesis in vivo is dependent on the 5' UTR of
cdk4 and, if so, whether the presence of wild-type p53 is
required for this effect. In addition, we have begun to elucidate the
role played by p53 in the downregulation of cdk4 translation
mediated by TGF-
. Our data indicate that this cytokine regulates
cdk4 translation through the direct actions of p53 upon the
cdk4 5' UTR.
 |
MATERIALS AND METHODS |
Cell culture, transfections, and reporter assays.
Mv1Lu
(ATCC CCL64) cells were maintained in Dulbecco's modified Eagle's
medium (DMEM) containing 10% fetal bovine serum in a 10%
CO2 humidified atmosphere. Cell lines expressing a
temperature-sensitive allele of p53 (ts-p53) (5) were
maintained in medium supplemented with 400 µg of G418 per ml. Cell
lines expressing exogenous cdk4 plasmids were maintained in
medium supplemented with 0.5 of puromycin per ml. Saos-2 cells were
maintained in DMEM supplemented with 10% fetal bovine serum
(Fetal-Clone I; Hyclone). Mv1Lu cells and Saos-2 cells were transfected
by the calcium phosphate coprecipitation method as previously described
(5). Release from contact inhibition and treatment with 50 pM TGF-
(R&D Systems) were done as previously described
(5).
For reporter assays, cells were washed twice with phosphate-buffered
saline, scraped and pelleted, and resuspended in 100 mM
KH2PO4 (pH 7.8). After three rounds of
freeze-thawing, the extracts were cleared by centrifugation and used
for luciferase assays (1).
Plasmids.
The mink cdk4 cDNA was amplified by PCR
with or without its 5' noncoding region and inserted into the
pCMVneoBam vector to create pCMVFLminkcdk4 and pCMV
5'minkcdk4. The
luciferase constructs contain the luciferase gene amplified by PCR and
ligated into pCMVneoBam. For expression of an RNA containing the
cdk4 5' UTR fused to the luciferase coding region, the
luciferase gene and the mink cdk4 5' UTR were each amplified
by PCR, the PCR products were digested with BamHI and
HindIII, and a three-way ligation with
BamHI-digested-pCMVneoBam was performed to generate
pCMVUTRluc. The DNA sequence of the cdk4 5' UTR
was verified. To generate 5'-deleted mink Cdk4 plasmids, the
cdk4 cDNA from pCMVFLminkcdk4, was isolated and
subcloned into pSp72 (Promega). The resulting plasmid,
pSp72FLminkcdk4, was either double digested with
EcoRV and PvuII and religated (PvuII),
double digested with EcoRV and BsrBI and
religated (
BsrBI), digested with SacI and
religated (
SacI), or double digested with
EcoRV and ThaI and religated (
ThaI). Each of these inserts was removed with
BamHI and BglII and ligated back into pCMVneoBam.
The p53 mutant plasmids [p53-
39, p53(40-359), p53-
96,
p53(97-359), p53-(311-393), p53-
347, p53-
360, p53-
380, and
p53-
390] were generated by PCR and ligated into pCMVneoBam. Mutants
p53-
96, p53(97-359), and p53-(311-393) contain an additional ATG
as a start codon. Sequencing analysis was used to verify each insert.
Metabolic labeling, immunoprecipitations, and Western blot
analysis.
Metabolic labeling and immunoprecipitations were
performed as previously described (5). For Western blotting,
cells were lysed in RIPA-B radioimmunoprecipitation assay buffer
(20 mM sodium phosphate [pH 7.4], 150 mM sodium chloride, 1% Triton
X-100, 10 µg of aprotinin per ml, 10 µg of leupeptin per ml, 5 mM phenylmethylsulfonyl fluoride). Cleared extracts (30 µg)
were electrophoresed on sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) gels and transferred to Immobulon-P
(Millipore) membranes. Affinity-purified anti-Cdk4 polyclonal antibody
(C-22; Santa Cruz Biotechnology, Inc.) was used for immunoblotting.
Polyclonal anti-Cdk4 antibody that was raised against recombinant
glutathione S-transferase (GST)-Cdk4 (generous gift of
C. J. Sherr) was used for immunoprecipitations.
Gel retardation assays.
Radiolabeled RNA probes (0.2 to 0.5 ng) were generated by in vitro transcription with T7 polymerase,
heated at 70°C, and quenched on ice prior to incubation with
0.3 ng of baculovirus-purified p53 (80% pure; generous gift of C. Prives) or Rev (generous gift of M. L. Zapp) in binding buffer (40 mM Tris-HCl [pH 7.9], 50 mM KCl, 1 µg of bovine serum albumin
[BSA] per µl, 1 mM dithiothreitol [DTT]) with 75 ng of tRNA, and
1 µl of RNasin (Promega) for 20 min. RNA-protein complexes were
resolved on 4% acrylamide gels and detected by autoradiography.
Immunoprecipitation-deoxycholate (IP-DOC) gel shifts were performed
essentially as described previously (22). Specifically,
immune complexes were washed two times with 100 mM NETN (100 mM KCl, 40 mM Tris-HCl [pH 7.9], 1 mM DTT, 0.1% NP-40) then twice with binding
buffer. The pellet was incubated with 0.8% DOC in binding buffer for
10 min on ice, NP-40 was added to 1.2%, and the sample was incubated
with radiolabeled probe, 75 ng of tRNA, and 1 µl of RNasin as
described above.
Northern blot analyses.
Northern blotting was performed as
previously described (5). To detect exogenous
cdk4 RNA, the blots were probed under high-stringency
conditions with an oligonucleotide that recognizes the sequence
encoding the hemagglutinin (HA) tag. To detect combined endogenous and
exogenous cdk4 levels, the blots were probed with a mink
cdk4 cDNA. To detect luciferase and cdk4
UTR-luciferase RNAs, a luciferase cDNA was used. Northern blots to
measure mink p15INK4b RNA were performed with RNA enriched
for poly(A)+. The probe was a fragment of the mink p15 cDNA
(19) (generous gift of J. Massagué) labeled to high
specific activity by PCR with a 5' primer corresponding to nucleotides
4 to 24 and a 3' primer corresponding to nucleotides 115 to 136 in the
human p15 sequence. To control for loading, the blots were stripped and probed with the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA.
In vitro translation assays.
RNAs (10 to 20 ng) were heated
at 70°C and quenched on ice before addition of binding buffer (40 mM
Tris-HCl [pH 8.0], 1 mM DTT, 50 mM NaCl), 5 to 8 ng of protein
(either p53 or BSA), 75 ng of tRNA, and 1 µl of RNasin (Promega). The
binding reaction mixtures were incubated at 37°C for 20 min, followed
by the addition of 20 µCi of [35S]methionine and
standard components of a rabbit reticulocyte lysate system (Promega).
Translation was allowed to proceed for 1 h at 30°C. Newly
synthesized proteins were subjected to SDS-PAGE and autoradiography.
 |
RESULTS |
The 5' UTR is required for Cdk4 downregulation.
In Mv1Lu
cells expressing an exogenous, murine cdk4 mRNA lacking
most of its 5' UTR and all of its 3' UTR, translation of this RNA fails
to be repressed in response to TGF-
(4, 5). This
suggested the possibility that TGF-
might regulate cdk4 translation through one or both of its UTRs. To test this hypothesis, we assessed whether the translational regulation of cdk4 by
TGF-
requires the 5' UTR of cdk4. Stable clones of
Mv1Lu cells that express an exogenous mink cdk4 mRNA
either containing the coding region with the entire 5' UTR (henceforth
referred to as the FL [full-length] cdk4 RNA) or
containing the coding region and only 21 bp of the 5' UTR (henceforth
referred to as
5' cdk4 RNA) were generated. In clones
expressing FL cdk4 RNA, the synthesis of exogenous Cdk4 was
inhibited to a similar degree as that of the endogenous Cdk4 (62% and
67% repression, respectively) following treatment with TGF-
(Fig.
1A). In contrast, in clones where the 5'
UTR of cdk4 was lacking, synthesis of this exogenous Cdk4
failed to be inhibited by TGF-
, while endogenous Cdk4 was still
efficiently downregulated. The greater degree of synthesis of Cdk4 from
the
5' cdk4 RNA compared with the FL cdk4 RNA
is likely due to the absence of the lengthy encumbered cdk4
5' UTR. The exogenous cdk4 RNA was expressed at similar
levels in clones expressing either the FL or
5' cdk4 RNA
or at increased levels in the FL clone relative to the
5' clone
(Fig. 1B). Thus, the presence of increased RNA levels is not an
explanation for
5' cdk4 failing to be downregulated by
TGF-
. The cdk4 mRNA levels were not affected by
TGF-
treatment, as determined by Northern blotting, consistent with
regulation occurring at the translational level (Fig. 1B). Together,
these observations suggest that TGF-
inhibits cdk4
translation only when the cdk4 mRNA contains its 5'
leader sequence.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 1.
5' UTR-deleted cdk4 is resistant to
downregulation by TGF- . (A) Parental Mv1Lu cells and subclones
stably expressing HA-tagged versions of the cdk4 RNA either
containing its entire 5' UTR (FL) or lacking its 5' UTR ( 5') were
treated with 50 pM TGF- for 20 h. During the last 3 h of
treatment, the cells were metabolically labeled with
[35S]methionine, and specific immunoprecipitations for
Cdk4 were then performed. Protein samples were electrophoresed in a
10% SDS-polyacrylamide gel. (B) RNA was harvested from parental and
Cdk4 clones untreated or treated for 17 h with TGF- , Northern
blotted, and probed sequentially with mink cdk4, an
oligonucleotide encoding the HA tag, and GAPDH, as indicated.
|
|
TGF-
-induced Cdk4 downregulation is mediated via its 5'
UTR.
To determine if the 5' UTR of cdk4 is sufficient
for sensitivity to TGF-
-induced translational downregulation,
Mv1Lu cell clones expressing an mRNA that contains the 5' UTR
of mink cdk4 fused to the coding region of the luciferase
reporter were generated. Following treatment with TGF-
, luciferase
activity was markedly downregulated in cells expressing this mRNA
(Fig. 2A, upper panel). In contrast, in control clones expressing luciferase RNA lacking the
cdk4 5' UTR, luciferase activity was unaffected by TGF-
treatment.


View larger version (96K):
[in this window]
[in a new window]
|
FIG. 2.
TGF- inhibits expression of a cdk4 5'
UTR-containing RNA. (A) (Top) Luciferase activity was measured in an
asynchronous population of Mv1Lu cells stably expressing either
luciferase mRNA without a 5' leader sequence (luc) or luciferase
mRNA fused to the cdk4 5' UTR (UTR-luc) that had been
incubated in the absence or presence of 50 pM TGF- for the indicated
lengths of time. Values are the percentage of luciferase activity in
treated populations relative to that in untreated populations harvested
at identical times (set to 100%). Experiments were done in triplicate.
Error bars indicate the standard deviation from the mean. (Middle) Cell
cycle distribution in parallel cultures was determined by flow
cytometry. Results from a representative experiment are shown. (Bottom)
RNA was collected at the indicated times and subjected to Northern
blotting with probes for luciferase (luc) or GAPDH. (B) Assays for
luciferase activity, cell cycle distribution, and Northern blotting
were performed as for panel A, except that the cultures were contact
inhibited for at least 3 days, trypsinized, and then replated into
growth medium in the absence or presence of TGF- . An arrow indicates
the time when untreated cells begin to enter S phase.
|
|
To determine if the time course of translational inhibition coincided
with the time course of TGF-
-induced cell cycle arrest, the clones
were analyzed at successive times following TGF-
treatment. Within
7 h of TGF-
treatment of actively proliferating cells, luciferase activity was downregulated by 30 to 40% in clones
expressing the cdk4 5' UTR-luciferase mRNA compared to
that in an untreated population (Fig. 2A). This was also roughly the
same time at which the cells began to accumulate in the G1
phase (Fig. 2A, middle panel). In clones expressing the luciferase
mRNA lacking the cdk4 5' UTR, TGF-
was without effect
on luciferase activity, despite the ability of these cells to undergo a
normal TGF-
-induced arrest. Luciferase RNA levels were also
unchanged by the cytokine, suggesting that regulation is occurring at
the level of translation (Fig. 2A, lower panel). Together, these
observations suggest that the cdk4 5' UTR is capable of
conferring responsiveness to TGF-
-induced translational
downregulation upon a heterologous RNA and that translational
repression of a cdk4 5' UTR-containing RNA occurs with a
time course similar to Cdk4 downregulation and coincides with or
precedes a TGF-
-induced growth arrest.
Because cells are only sensitive to the antiproliferative and Cdk4
inhibitory effects of TGF-
when exposed to the cytokine in early to
mid-G1 phase (4, 13), we repeated the above
experiment with cells that were treated with TGF-
immediately
following release from a contact-inhibited, quiescent state. TGF-
treatment of cells expressing the cdk4 5' UTR-luciferase
mRNA following release from quiescence resulted in a rapid
reduction in luciferase activity compared with untreated cells also
released from quiescence (Fig. 2B). Luciferase activity was repressed
by approximately 20% within 9 h of TGF-
treatment following
release from contact inhibition, which was prior to the time when
untreated cells began to enter S phase. Similar results are also
observed for inhibition of Cdk4 by TGF-
. Luciferase activity in
control cells that express a luciferase RNA without the cdk4
5' UTR was again unchanged by TGF-
treatment under these conditions.
The luciferase RNA levels in TGF-
-treated cells were also unchanged
by the cytokine, supporting our hypothesis that reduction in luciferase
activity following TGF-
treatment is regulated at the translational
level (Fig. 2B). These results, like those from experiments with
proliferating cells, demonstrate a strong correlation between the time
during which downregulation of Cdk4 occurring through its 5' UTR takes place and the time during which TGF-
induces cell cycle arrest.
Wild-type p53 is required for TGF-
-induced, 5' UTR-dependent
downregulation of Cdk4.
Previously we demonstrated that in cells
expressing mutant p53, Cdk4 synthesis fails to be inhibited by TGF-
(5). In these studies, Mv1Lu cell clones that expressed
ts-p53 (Val 135) were used. When the cells were cultured at the
nonpermissive temperature (39°C, mutant p53), they failed to arrest
and to inhibit Cdk4 synthesis in response to TGF-
. Parental
Mv1Lu cells express wild-type p53, and in the ts-p53 clones grown
at the nonpermissive temperature, the mutant form of p53 acts in a
dominant-negative manner over endogenous p53 (5). We asked
if the p53-dependent Cdk4 downregulation by TGF-
also requires the
5' UTR of cdk4 by generating ts-p53 clones that express
either of the two mink cdk4-HA mRNAs (FL and
5')
described above. When ts-p53 cells expressing an exogenous FL
cdk4 RNA containing its entire 5' UTR were cultured at
32°C (wild-type p53), synthesis of both exogenous and endogenous Cdk4 was inhibited in response to TGF-
(Fig.
3A). In contrast, when the cells were
cultured at the nonpermissive temperature, neither endogenous nor
exogenous Cdk4 was downregulated in response to TGF-
. Importantly,
in ts-p53 cells expressing exogenous
5' cdk4 RNA that
lacks a 5' UTR, the exogenous Cdk4 failed to be downregulated by
TGF-
treatment at either 32 or 39°C, supporting the notion that
inhibition of Cdk4 synthesis is mediated via the 5' UTR. Although the
levels of exogenous Cdk4-HA protein were unexpectedly lower after
culture at 39°C compared to those at 32°C, this was a consequence
of changes in RNA abundance (Fig. 3B) and thus was likely due to
changes in transcriptional activity of the cytomegalovirus (CMV)
promoter used to drive expression of exogenous Cdk4-HA. Northern blot
analysis also confirmed that although Cdk4 protein levels were
repressed by TGF-
under conditions in which p53 is present in its
wild-type form, the mRNA levels were unaltered by TGF-
treatment
(Fig. 3B). These observations are consistent with the requirement for
wild-type p53 in TGF-
-mediated Cdk4 downregulation (5)
and indicate that the 5' UTR of cdk4 is essential in this
setting.

View larger version (64K):
[in this window]
[in a new window]
|
FIG. 3.
The 5' UTR of cdk4 mediates p53 dependence in
TGF- -induced translational inhibition of cdk4. (A)
Mv1Lu cells expressing a temperature-sensitive allele of p53 (LTR5)
(5) and derivative cell lines expressing exogenous
cdk4 either containing its entire 5' UTR (FL) or lacking its
5' UTR ( 5') were cultured at the permissive temperature (32°C) or
the nonpermissive temperature (39°C) in the presence or absence of
TGF- for 27 h (32°C) or 24 h (39°C). Whole-cell
lysates were prepared and analyzed by Western blotting with specific
antiserum to Cdk4. A shorter exposure time for the 5' clones is
shown to emphasize the resistance to TGF- -induced downregulation for
the exogenous, HA-tagged Cdk4. The membranes were stripped and blotted
with antitubulin antibody as a loading control. (B) Northern blot
analysis of RNA harvested from the Mv1Lu derivative lines in panel
A after culture at the indicated temperatures in the presence or
absence of TGF- . After probing with a Cdk4 cDNA, the membranes were
sequentially stripped and reprobed with an oligonucleotide encoding the
HA tag and then a GAPDH cDNA. (C) Luciferase activity was measured in
Mv1Lu cells expressing both a temperature-sensitive allele of p53
and either luciferase mRNA without a 5' leader sequence
(luciferase) or luciferase mRNA fused to the cdk4 5' UTR
(CDK4 5' UTR-luciferase) that had been cultured as described for panel
A. The bar graph shows luciferase activity after TGF- treatment
relative to untreated cell populations cultured under the same
conditions (set at 100). Experiments were done in triplicate. Error
bars indicate the standard deviation from the mean. (D) Northern blot
analysis of RNA harvested from the Mv1Lu derivative lines shown in
panel C. Membranes were probed with a luciferase cDNA (luc), stripped,
and reprobed with a GAPDH cDNA.
|
|
We next asked whether the 5' UTR of cdk4 was sufficient for
TGF-
-induced translational inhibition in a p53-dependent manner. Mv1Lu ts-p53 clones that expressed either the cdk4 5'
UTR-luciferase mRNA or the luciferase RNA lacking a 5' UTR
(described above) were generated. When cells expressing the
cdk4 5' UTR-luciferase mRNA were cultured at 32°C,
luciferase activity was markedly reduced in TGF-
-treated cells
compared to untreated populations (Fig. 3C). In cells expressing the
mRNA without the cdk4 5' UTR, luciferase activity was
unaffected by TGF-
treatment. When the cells were cultured at
39°C, luciferase activity was not affected by TGF-
in either
clones expressing luciferase mRNA or in clones expressing the
cdk4 5' UTR-luciferase mRNA, consistent with the notion
that the 5' UTR of cdk4 is sufficient to mediate
p53-dependent translational inhibition induced by TGF-
. Analysis of
luciferase RNA levels by Northern blotting supported the idea that
regulation of luciferase activity by TGF-
was occurring at the
translational level because the RNA levels were unchanged under the
same conditions in which repression of luciferase activity is observed
(Fig. 3D).
Wild-type p53 can bind the Cdk4 mRNA.
Given our
observations that translational inhibition of Cdk4 (by TGF-
)
required p53 and the cdk4 5' UTR, along with reports that
p53 has a high affinity for single-stranded RNA and possesses nucleic
acid reannealing (antihelicase) activity, we hypothesized that p53 was
directly involved in regulating Cdk4 translation and might bind to the
cdk4 RNA (5' UTR) as part of the mechanism by which it
inhibits Cdk4 translation. We assessed whether p53 could interact with
the cdk4 RNA by gel shift analysis using
baculovirus-purified recombinant p53 and a radiolabeled cdk4
5' UTR RNA. Using this assay, we detected a specific RNA-protein
complex that contained p53. The presence of p53 was demonstrated by the
ability of p53-specific antibodies to shift the mobility of the complex
(Fig. 4A). To test the specificity of
this interaction, a nonspecific probe, the Rev responsive element (RRE)
(27) in an RNA of a similar size and G-C content was used.
p53 bound selectively to the cdk4 RNA, because only weak
binding to the nonspecific RNA was detected (Fig. 4B). In contrast, the
HIV-1 Rev protein was capable of interacting specifically with the RRE,
its RNA target, but not with the cdk4 RNA (Fig. 4B). The
weak interaction observed between p53 and the RRE probe is likely due
to p53's ability to bind nonspecifically to RNA (10). The
specificity of the complex was confirmed by competition experiments. An
excess of unlabeled cdk4 5' UTR RNA successfully competed
for the interaction between p53 and the radiolabeled cdk4
RNA, whereas the RRE RNA and the reverse complement of the CDK4 5' UTR
were much less effective at competing for binding to p53 (Fig. 4C).
Again, p53's weak nonspecific RNA binding activity is the likely
reason that the RRE and the antisense cdk4 5' UTR RNAs were
able to partly compete for p53 binding.

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 4.
Wild-type p53 can bind selectively to the
cdk4 5' UTR RNA. (A) Baculovirus-purified p53 was analyzed
for RNA binding activity in a gel shift assay with
32P-labeled cdk4 5' UTR (230 nucleotides) as a
probe. Addition of monoclonal anti-p53 antibodies (Bp53-12, DO-I)
induced a "supershift" of the RNA-protein complex. Migration of the
probe in the absence of added protein is shown in the first lane ( ).
(B) The specificity of p53's interaction with RNA was analyzed by gel
shift with either the RRE or the cdk4 5' UTR as a probe.
Migrations of free, unbound RRE, and cdk4 5' UTR probes are
shown in the first and fourth lanes, respectively ( ). Binding of
baculovirus-purified Rev protein to its target sequence, the RRE, is
indicated by the large arrow. Binding of p53 to the RRE or the
cdk4 5' UTR is indicated by the small arrow. The
autoradiograph in panel B was exposed for approximately twice as long
as those in panel A, C, or D to show the weak binding of p53 to the
RRE. (C) Increasing amounts of unlabeled RNA were included in the gel
shift reactions to compete for binding to p53. In the left panel, 13- to 40-fold molar excess of competitor RNA compared to labeled RNA was
included. In the right panel, 100- to 400-fold molar excess of
competitor RNA was included. specific, cdk4 5' UTR;
antisense, the reverse complement of cdk4 5' UTR. (D) Saos-2
cells were transfected with either wild-type p53, a mutant form of p53
(143A), or vector alone. After transfection, p53 was immunoprecipitated
(IP) with the indicated antibodies, released by DOC treatment, and used
in gel shift analysis. (Bottom panel) immunoprecipitates prepared in
parallel were resolved on SDS-PAGE and blotted with anti-p53 antibody.
Bac-p53, p53 purified from recombinant baculovirus.
|
|
As an alternative approach to assess p53's ability to bind the
cdk4 5' UTR, we used p53 isolated in vivo from mammalian
cells. Following transfection of p53-expressing plasmids into Saos-2 cells (which lack endogenous p53), p53 was immunoprecipitated and the
immune complexes were treated with sodium deoxycholate (DOC) to release
p53, which was then used in RNA gel shift analysis. Wild-type p53
isolated in this way bound to the cdk4 5' UTR RNA as well as
the baculovirus-purified form (Fig. 4D). In contrast, immunoprecipitation of a mutant form of p53 (143A) failed to generate an RNA-protein complex. A control monoclonal antibody (MAb 240) that
does not recognize wild-type p53 was unable to immunoprecipitate proteins that bound to the cdk4 5' UTR. Similarly, if the
cells were transfected with vector alone, an RNA-protein complex was not detected. Together, these observations suggest that wild-type p53,
but not a mutant form of p53, can interact specifically with the 5' UTR
of the cdk4 RNA.
Wild-type p53 inhibits Cdk4 translation in vitro.
Interaction
with the cdk4 RNA could provide a means for p53 to regulate
cdk4 translation. Prior to initiation of translation, the
ribosome is thought to progressively scan the 5' UTR for potential start codons (11, 12). With p53 bound to the cdk4
5' UTR, ribosomal scanning could be sterically hindered, resulting in 40S subunit stalling and the failure of translation to initiate. To
determine if p53 can directly inhibit cdk4 translation, we translated cdk4 in vitro, using rabbit reticulocyte lysates,
in the presence or absence of p53 or in the presence of another
protein, BSA. Translation of either human or mink cdk4 RNA
containing their respective 5' UTR was markedly inhibited by the
presence of p53. In contrast, translation of RNAs lacking a 5' UTR was
completely unaffected by the presence of p53 (Fig. 5A and
B). Given that the cdk4 5' UTR
contains features that are known to markedly inhibit translation, we
were not surprised to observe that the cdk4 RNA lacking its
5' UTR was consistently translated more efficiently than the
cdk4 RNA containing its cognate 5' UTR. A mutant form of
p53, 143A, shown to be incapable of binding RNA (Fig. 4D)
(17), was defective for cdk4 translational
repression (Fig. 5B).

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 5.
Wild-type p53 can repress cdk4 translation in
a cell-free assay. (A, top panel) In vitro translation of human
cdk4 from either a cdk4 RNA containing its entire
5' UTR (full-length CDK4) or a cdk4 RNA lacking a 5' UTR
( 5' CDK4) in the presence of BSA ( ) or baculovirus-purified p53
protein (+). Samples of the in vitro translation mixtures were analyzed
on a 10% SDS-polyacrylamide gel. (A, bottom panel) Parallel assays
were conducted in which the RNA was collected both preceding and
following incubation in the cell-free translation assay and
subsequently analyzed by Northern blotting with Cdk4 cDNA as a probe.
retic, reticulocyte. (B) In vitro translation of mink cdk4
in the presence of baculovirus-purified wild-type (wt) or mutant (143A)
p53. Samples were analyzed as in panel A. (C) [top panel]) In vitro
translation of luciferase from either an RNA containing the
cdk4 5' UTR fused to the luciferase coding region (CDK4 5'
UTR-luciferase) or from an RNA lacking a 5' UTR ( 5' luciferase) in
the presence of BSA ( ) or baculovirus-purified p53 protein (+).
Samples were analyzed as in panel A. (C [bottom panel]) Same as panel
A, bottom panel, except a luciferase cDNA was used as a probe for the
Northern blot.
|
|
To ascertain whether the 5' UTR of cdk4 alone could mediate
p53-induced translational inhibition, luciferase RNAs either lacking a
5' noncoding sequence or containing the cdk4 5' UTR were
translated in the absence or presence of p53. p53 inhibited translation
from the cdk4 5' UTR-containing transcript, but had no
effect on the luciferase RNA that lacked a 5' noncoding region (Fig.
5C). Because the abundance of the UTR-containing transcripts was as
constant as that of the transcripts lacking a 5' UTR following
incubation with p53 and reticulocyte lysates (Fig. 5, lower panels),
these results cannot be explained by differential stabilities of the transcripts. Our observations that wild-type p53 can inhibit
translation of an RNA containing the cdk4 5' UTR, together
with the previous demonstration that p53 can bind to the
cdk4 5' UTR (Fig. 4), suggest that translational inhibition
may occur as a result of a p53-RNA interaction.
Selective RNA binding and regulation by p53 require the region from
100 to
64 in the cdk4 5' UTR.
To localize the
region of the cdk4 RNA required for p53 interaction, we
tested a series of cdk4 5' UTR deletion mutants for their
ability to bind p53 (Fig. 6A).
cdk4 cDNAs with deletion of up to the first 127 nucleotides
remained capable of binding to p53 by gel shift analysis (Fig. 6B).
However, deletion of an additional 36 nucleotides from the
cdk4 RNA rendered the RNA incapable of interaction with p53.
To exclude the possibility that an RNA be of a minimal length for p53
binding, we tested a second set of deletion constructs that were each
lengthened by the addition of 53 nucleotides of the cdk4 RNA
coding region. We observed an identical pattern of binding by gel shift
analysis when comparing the longer RNA probes with the shorter matched
RNAs (not shown). This observation suggests that p53 interaction is
determined by a specific region of the RNA and not its length. In
either situation, deletion to position
64 (relative to the initiating
AUG) in cdk4 created an RNA molecule that no longer
interacted with p53.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 6.
Localization of the RNA region in ~cdk4
that is essential for p53 interaction and p53-induced repression. (A)
Schematic representation of the Cdk4 plasmids used that express RNAs
containing 5' UTRs of various lengths. (B) 32P-labeled
cdk4 5' UTR RNAs were synthesized in vitro from the plasmids
noted in panel A, incubated with baculovirus-purified p53 protein at
either 25°C (lanes 2, 5, 8, and 11) or 37°C (lanes 3, 6, 9, and
12), and subjected to gel shift analysis. (C) Saos-2 cells were
transfected with various derivatives of CMV driven mink cdk4
with or without wild-type human p53 expression plasmid. After
transfection, cells were metabolically labeled, and specific
immunoprecipitations for Cdk4 were performed. Samples were analyzed on
a 10% SDS-polyacrylamide gel. (D) Saos-2 cells were transfected as
described above. After transfection, total RNA was harvested and used
for Northern analysis. The blot was probed with a Cdk4 cDNA and
reprobed with GAPDH.
|
|
We next asked whether the ability of p53 to bind to the cdk4
5' UTR correlated with its ability to repress cdk4
translation. To address this question, expression vectors for Cdk4 and
wild-type p53 were cotransfected into the p53-null Saos-2 cells, and
synthesis of Cdk4 protein was monitored by metabolic labeling and
immunoprecipitation. When cdk4 cDNAs with deletion of up to
the first 127 nucleotides were cotransfected with p53, p53 inhibited
their translation to an extent similar to that of the FL RNA (Fig. 6C).
However, similar to the RNA binding results, deletion of an additional
36 nucleotides from the RNA rendered cdk4 nearly insensitive
to p53 regulation. Repression of Cdk4 synthesis by p53 was not a
consequence of changes in cdk4 RNA levels, as demonstrated
by Northern blotting, consistent with our hypothesis that p53
regulates Cdk4 at the translational level. Taken together with
the gel shift results, these findings suggest that the region in the
cdk4 RNA from
100 to
64, relative to the initiating AUG,
is essential for both p53 interaction and p53-mediated translational regulation.
Analysis of p53 mutants for abilities to bind cdk4 RNA
and repress its translation.
To determine what aspects of the p53
protein are involved in translational regulation and RNA binding, we
utilized a panel of p53 mutants in the cotransfection and gel shift
assays. The p53 protein can be divided into distinct domains defined in
terms of separable activities. These include a transcriptional
activation region at the N terminus (residues 1 to 43), a
sequence-specific DNA-binding domain (residues 100 to 300), an
oligomerization domain (residues 320 to 360), and a carboxy-terminal
domain containing activities for nonspecific nucleic acid binding and
nucleic acid reannealing (antihelicase) (residues 330 to 393)
(10).
First we determined whether p53-regulated translational control of
cdk4 can occur through a p53 transcriptional
transactivation-independent pathway by using a transcriptionally inert
mutant of p53 lacking the N-terminal 39 amino acids. Coexpression of
Cdk4 with such an N-terminally-deleted mutant of p53 in Saos-2 cells
caused inhibition of Cdk4 expression when the FL cdk4 cDNA
was used, but not when the
5' cdk4 cDNA was used, similar
to the actions of wild-type p53 (Fig.
7B). In contrast, mutants of p53 missing
larger regions of the N terminus (p53-
79 and p53-
96) were
incapable of regulating Cdk4 synthesis (Fig. 7B and Table
1). When tested for binding to the
cdk4 RNA, the shorter N-terminally-deleted p53 (
39) bound as well as wild-type p53, and p53s harboring larger deletions of the N
terminus (
79 and
96), although defective for translational control, could still bind reasonably well to the cdk4 RNA
(Fig. 7C and Table 1). Together, these data suggest that the
transcriptional transactivation domain of p53 is not required, but the
region between amino acids 43 and 80 is essential for p53 to regulate translation of cdk4. Moreover, these results suggest that
functions of p53 in addition to its ability to bind RNA are required
for translational inhibition.

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 7.
Analysis of p53 mutants for RNA binding and
translational regulation capabilities. (A) Expression of wild-type and
mutant forms of p53 following transfection into Saos-2 cells was
assayed by immunoblotting with a mixture of the monoclonal antibodies
PAb240 and PAb421. (B) Saos-2 cells were transfected with either human
CDK4 containing its 5' UTR or lacking its 5' UTR and with or without
wild-type p53 or mutant forms of p53. Following transfection, cells
were metabolically labeled, and specific immunoprecipitations for Cdk4
were performed. (C) Saos-2 cells were transfected with wild-type and
mutant forms of p53. Following transfection, p53 was immunoprecipitated
with anti-p53 antibodies, released by DOC treatment, and analyzed by
gel shift with a 32P-labeled cdk4 5' UTR
riboprobe, except in those lanes (labeled RRE) where the RRE was used
as the riboprobe. The p53(311-393)-Cdk4 protein-RNA complex is
indicated by the large arrow, and the p53(311-393)-RRE protein-RNA
complex is indicated by the small arrow. FREE, riboprobe without
addition of immunoprecipitated protein.
|
|
To determine whether the ability of p53 to regulate translation and
bind to the cdk4 RNA might be dependent upon an intact C-terminal region, mutants of p53 truncated at the carboxy terminus were tested. p53 mutants that were lacking up to 33 residues from the C terminus, p53(1-360), p53(1-370), p53(1-380), and p53(1-390), were still capable of inhibiting Cdk4 synthesis in cotransfection assays. These mutants also bound to the cdk4 RNA in a manner
similar to wild-type p53. On the other hand, mutants of p53 that were lacking larger portions of the C terminus [p53(1-291), p53(1-343), and p53(1-347)] were incapable of interacting with the CDK4 5' UTR
and failed to regulate cdk4 translation (Fig. 7B and Table 1). To exclude the possibility that p53 mutants lacking larger regions
of the C terminus were defective for translational regulation and
specific RNA binding because they had lost their ability to oligomerize, we tested a p53 molecule that contains p53(1-343) fused
to the GCN4 dimerization domain (p53-GCN4) (17).
Reconstitution of dimerization function did not rescue the ability of
p53(1-343) to either inhibit Cdk4 synthesis or bind to the
cdk4 RNA, suggesting that the inability to dimerize does not
explain why these mutants fail to inhibit Cdk4 expression (Table 1).
Thus, our observations suggest that in the context of the full-length
protein, the extreme C-terminal region of p53 (amino acids 360 to 393)
is dispensable for translational regulation and specific RNA binding,
while adjacent regions (N terminal to residue 360) are essential. In
addition, we found that p53 lacking both N- and C-terminal domains
[p53(40-359)] still inhibited Cdk4 synthesis and could also bind
effectively to the cdk4 RNA. However, elimination of amino
acids 40 to 96 from this mutant, resulting in p53(97-359), completely
abolished these activities, illustrating the necessity for these
residues (Fig. 7B and Table 1). This result is consistent with our
findings that p53-
96 fails to regulate Cdk4 translation.
When an isolated carboxy domain of p53 (residues 311 to 393) was tested
for its ability to repress Cdk4 synthesis, we observed some inhibition
of Cdk4 synthesis, albeit not to the same extent as with the wild-type
protein. Thus, the p53 C-terminal fragment alone (amino acids 311 to
360) may have some intrinsic ability to regulate cdk4
translation in this system. This fragment of p53 was also competent for
binding to the cdk4 RNA, yet it bound to the nonspecific
RNA, the RRE, as well as it did to the cdk4 RNA (Fig. 7).
Given that a nonspecific nucleic acid binding region has been mapped to
residues 330 to 393, these data suggest that interactions through the C
terminus may be entirely nonspecific, while other regions of the p53
molecule could provide specificity. Because p53(311-393) has lost its
ability to selectively recognize the cdk4 RNA, these data
also suggest that nonspecific RNA binding and specific RNA binding can
be genetically separated.
 |
DISCUSSION |
Treatment with TGF-
potently inhibits Cdk4 synthesis and causes
a cell cycle arrest in G1 phase. Here, we employed
Mv1Lu cells to test in vivo the necessity for the cdk4
5' UTR in Cdk4 downregulation in response to TGF-
. We show, for the
first time, that the 5' UTR of the cdk4 mRNA is
essential for TGF-
-mediated cdk4 translational inhibition
and, moreover, that this region of the cdk4 RNA can confer
TGF-
-induced translational regulation upon a heterologous RNA.
TGF-
-mediated translational regulation through the cdk4
5' UTR occurs with similar kinetics as does endogenous Cdk4 regulation
in response to TGF-
, consistent with the possibility that
TGF-
-mediated Cdk4 regulation occurs entirely through the 5' UTR. In
addition, the 5' UTR of cdk4 is both necessary and sufficient for p53-dependent regulation of cdk4 in response
to TGF-
. p53 is not only capable of binding to a specific region of
the cdk4 5' UTR, but also can directly repress Cdk4
translation in vitro. Together, our data support a model in which
TGF-
inhibits cdk4 translation via p53 interaction with
the cdk4 5' UTR. Given the importance of downregulating Cdk4
in the TGF-
growth arrest pathway, consideration of these results is
crucial to understanding the mechanisms of TGF-
action.
Our hypothesis that p53 may have a direct role in regulating
cdk4 translation in response to TGF-
in vivo is
consistent with several lines of evidence pointing to a role for p53 in
protein translation. Cytoplasmic p53 has been found in association with ribosomes (7), and p53 has been reported to regulate its own translation via its 5' leader sequence (16). p53 has also
been detected in complexes containing the L5 ribosomal protein
(15), has been found to be covalently bound to the 5.8S
ribosomal RNA (6, 21), and has a higher binding affinity for
RNA than for DNA (17). While we have shown that p53 can
interact with the cdk4 RNA and can inhibit translation of
RNAs containing the 5' UTR of cdk4, our results do not
distinguish between p53 directly contacting the cdk4 RNA and
p53 interacting with the RNA through an associated molecule. Thus,
although we propose that p53 directly regulates cdk4
translation in vivo, we cannot exclude other indirect roles for p53.
Importantly, we found that RNA binding by p53 is necessary but
insufficient for optimal translational inhibition. Thus, the mechanism
by which p53 regulates translation is most likely due to a dynamic
activity (e.g., catalytic) of the protein rather than a passive result
of p53 binding stoichiometrically to the RNA, consistent with the
findings of others (16).
The abilities to bind nonspecifically to nucleic acids, to reanneal
nucleic acids, and to inhibit helicases are all activities of p53 that
have been mapped to the C-terminal region (residues 311 to 393) of the
protein (10). Our results suggest that in the context of the
full-length protein, the carboxy-terminal 33 amino acids of p53 are
dispensable for translational regulation and specific RNA binding, but
an adjacent region (residues 347 to 360) is essential for these
activities. The antihelicase and reannealing activities attributed to
p53 might allow it to inhibit the translation of cdk4 by
stabilizing hairpin structures in the 5' UTR by promoting pairing of
matched strands of RNA and/or by inhibiting unwinding. Our results
suggest that reannealing is not equivalent to specific RNA binding.
Although a truncated p53 protein encompassing amino acids 311 to 393 is
sufficient to promote nucleic acid reannealing (26) we found
that this domain alone, in contrast to the full-length protein, lacks
the ability to recognize specific RNA fragments. Moreover, the
p53-
360 mutant retains specific RNA binding, but the alternative
spliced form of murine p53 (which lacks amino acids 364 to 390 and
contains 17 new residues) cannot reanneal nucleic acids
(26). Our observation that this C-terminal fragment (amino
acids 311 to 393) of p53 is partially defective for translational
regulation also suggests that the reannealing activity of p53 is
insufficient to modulate translation. Moreover, the ability to
recognize specific RNA as opposed to nonspecific binding is a
requirement for optimal translational regulation. Finally, these
results suggest that specific and nonspecific RNA binding by p53 can be
genetically separated. p53 mutants that retain an intact C-terminal
domain but lack other regions of the protein (
79 and
96) are
completely defective for translational regulation, but bind to RNA.
This suggests an interplay between protein domains, possibly involving
negative regulation. Altogether, the C-terminal functions of p53 most
likely depend upon communication with the rest of the protein, similar
to the manner in which the C-terminal region of p53 regulates the
sequence-specific DNA binding activity of its core domain
(14). Finally, since p53 is a predominantly nuclear protein,
it may bind to the target RNA in the nucleus and alter its capacity to
be translated prior to its export into the cytoplasm.
The results described here show striking parallels to another
p53-dependent growth arrest pathway. Growth arrest by the Gas1 membrane-associated protein has been demonstrated to require p53 (3). Moreover, the N-terminal transcriptional
transactivation-containing domain of p53 is dispensable for this arrest
(3). Thus, the requirement for p53 in the Gas1 growth arrest
pathway requires a function separate from its transcriptional
transactivation. This result is analogous to our findings that p53
translational inhibition of cdk4 does not require the N
terminus of p53. Moreover, both p53-dependent growth arrest by Gas1 and
p53-dependent growth arrest by TGF-
share a requirement for the
proline-rich region of p53 extending from amino acid 61 to amino acid
94. Our observations that the p53-
39 mutant retains the ability to
regulate Cdk4 synthesis and that p53-
96 and p53-
79 mutants were
defective for translational regulation of cdk4 suggest that
residues 43 to 80 of p53 are important for this function. Growth arrest
by Gas1 was shown to require residues 63 to 85 of p53, and mutation of
four prolines in this region eliminated p53's ability to cooperate
with Gas1 in promoting a G1 phase arrest (20).
In a third setting, H1299 cells, a p53 mutant lacking this proline-rich
region is competent to activate transcription, but cannot inhibit
proliferation (24). Proline-rich domains are thought to
provide an interaction surface for SH3 domains. A role for SH3
interactions involving RNA-binding proteins is not unprecedented
(23, 25). Since many SH3-containing molecules are involved
in signaling from the cell surface, the proline-rich region of p53
could act as a receptor for signals transduced from the TGF-
receptor. Together these observations suggest that the p53 function
required in the Gas1 pathway, like the TGF-
pathway, might be
translational regulation.
We found that a specific RNA region in the cdk4 5' UTR could
mediate both RNA binding by p53 and translational inhibition by p53.
This region (from nucleotides
100 to
64 relative to the initiating
AUG), is predicted to be part of a stable hairpin structure in the
context of the entire 5' UTR. Interestingly, disruption at nucleotide
position
64 severs one of the most conserved regions in the
cdk4 5' UTR. From position
72 to position
53, the
sequence is 84% identical across four species: human, mink, pig, and
rat. Thus, this sequence or the structure it acquires is likely to be
critical to cdk4 regulation. Given that deletion of small
segments can dramatically change the predicted secondary structure of
an RNA, further studies involving mutagenesis of single nucleotides
that subtly disrupt the RNA structure will be most informative in
defining whether p53 is recognizing a specific RNA secondary structure.
TGF-
growth inhibition might occur via multiple mechanisms dependent
on several factors and/or environmental conditions. Our results suggest
that in mink lung epithelial cells, wild-type p53 is essential to
TGF-
-mediated cell cycle arrest. p53 is necessary for translational
regulation of cdk4 through its 5' UTR in these cells, and a
link between the effects of p53 on cdk4 translation and
TGF-
-mediated growth arrest is indicated.
 |
ACKNOWLEDGMENTS |
We thank Carol Prives for supplying purified p53 protein; Maria
Zapp for providing purified Rev protein and for help with the RNA gel
shift assay; Peter Howley, Arnold Levine, Jennifer Pietenpol, and Karen
Vousden for p53 mutant expression plasmids; Joan Massagué for the
mink p15 cDNA; Charles Sherr for GST-Cdk4; and Bert Vogelstein for
the pCMVneoBam vector. We also thank Peter Adams, Justin Lamb,
Christine McMahon, Elizabeth Neuman, and Monique Yoakim for critical
reading of the manuscript; Xiaoping He and Teena Kohli for excellent
technical assistance; and our colleagues for valuable discussions.
S.J.M. was supported by a fellowship from the American Cancer Society.
T.S. was supported by a fellowship from the National Institutes of
Health. G.P.Z. is supported by grant CA63230 from the National Cancer
Institute, by Cancer Center Core grant 5 P30 CA21765, and by the
American Lebanese Syrian Associated Charities (ALSAC) of St. Jude
Children's Research Hospital. This work was supported by grants from
the National Cancer Institute (CA65842) and the Dana-Farber/Sandoz Drug
Discovery Program to M.E.E. M.E.E. is a Scholar for the Leukemia
Society of America.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Dana-Farber
Cancer Institute and Harvard Medical School, 44 Binney St., Boston, MA 02115. Phone: (617) 632-2206. Fax: (617) 632-5417. E-mail:
mark_ewen{at}dfci.harvard.edu.
Present address: Cancer Biology Program, Division of
Hematology-Oncology, Department of Medicine, Beth Israel Deaconess
Medical Center and Harvard Medical School, Boston, MA 02215.
Present address: Department of Biochemistry, Faculty of Science,
Mahidol University, Bangkok 10400, Thailand.
 |
REFERENCES |
| 1.
|
Ausubel, F. M.,
R. Brent,
R. E. Kingston,
D. D. Moore,
J. G. Seidman,
J. A. Smith, and K. Struhl.
1996.
Current protocols in molecular biology.
Greene and Wiley Interscience, New York, N.Y.
|
| 2.
|
Datto, M. B.,
Y. Li,
J. F. Panus,
D. J. Howe,
Y. Xiong, and X. F. Wang.
1995.
Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism.
Proc. Natl. Acad. Sci. USA
92:5545-5549[Abstract/Free Full Text].
|
| 3.
|
Del Sal, G.,
E. M. Ruaro,
R. Utrera,
C. N. Cole,
A. J. Levine, and C. Schneider.
1995.
Gas1-induced growth suppression requires a transactivation-independent p53 function.
Mol. Cell. Biol.
15:7152-7160[Abstract].
|
| 4.
|
Ewen, M. E.,
H. K. Sluss,
L. L. Whitehouse, and D. M. Livingston.
1993.
TGF- inhibition of cdk4 synthesis is linked to cell cycle arrest.
Cell
74:1009-1020[CrossRef][Medline].
|
| 5.
|
Ewen, M. E.,
C. J. Oliver,
H. K. Sluss,
S. J. Miller, and D. S. Peeper.
1995.
p53-dependent repression of CDK4 translation in TGF- -induced G1 cell-cycle arrest.
Genes Dev.
9:204-217[Abstract/Free Full Text].
|
| 6.
|
Fontoura, B. M. A.,
E. A. Sorokina,
E. David, and R. B. Carroll.
1992.
p53 is covalently linked to 5.8S rRNA.
Mol. Cell. Biol.
12:5145-5151[Abstract/Free Full Text].
|
| 7.
|
Fontoura, B. M. A.,
C. A. Atienza,
E. A. Sorokina,
T. Morimoto, and R. B. Carroll.
1997.
Cytoplasmic p53 polypeptide is associated with ribosomes.
Mol. Cell. Biol.
17:3146-3154[Abstract].
|
| 8.
|
Hannon, G. J., and D. Beach.
1994.
p15INK4B is a potential effector of TGF- -induced cell cycle arrest.
Nature
371:257-261[CrossRef][Medline].
|
| 9.
|
Iavarone, A., and J. Massague.
1997.
Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF- in cells lacking the CDK inhibitor p15.
Nature
387:417-422[CrossRef][Medline].
|
| 10.
|
Ko, L. J., and C. Prives.
1996.
p53: puzzle and paradigm.
Genes Dev.
10:1054-1072[Free Full Text].
|
| 11.
|
Kozak, M.
1991.
An analysis of vertebrate mRNA sequences: intimations of translational control.
J. Cell Biol.
115:887-903[Abstract/Free Full Text].
|
| 12.
|
Kozak, M.
1999.
Initiation of translation in prokaryotes and eukaryotes.
Gene
234:187-208[CrossRef][Medline].
|
| 13.
|
Laiho, M.,
J. A. DeCaprio,
J. W. Ludlow,
D. M. Livingston, and J. Massagué.
1990.
Growth inhibition of TGF- linked to suppression of retinoblastoma protein phosphorylation.
Cell
62:175-185[CrossRef][Medline].
|
| 14.
|
Levine, A. J.
1997.
p53, the cellular gatekeeper for growth and division.
Cell
88:323-331[CrossRef][Medline].
|
| 15.
|
Marechal, V.,
B. Elenbaas,
J. Piette,
J.-C. Nicolas, and A. J. Levine.
1994.
The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes.
Mol. Cell. Biol.
14:7414-7420[Abstract/Free Full Text].
|
| 16.
|
Mosner, J.,
T. Mummenbrauer,
C. Bauer,
G. Sczakiel,
F. Grosse, and W. Deppert.
1995.
Negative feedback regulation of wild-type p53 biosynthesis.
EMBO J.
14:4442-4449[Medline].
|
| 17.
|
Oberosler, P.,
P. Hloch,
U. Ramsperger, and H. Stahl.
1993.
p53-catalyzed annealing of complementary single-stranded nucleic acid.
EMBO J.
12:2389-2396[Medline].
|
| 18.
|
Pientenpol, J. A.,
T. Tokino,
S. Thiagalingam,
W. S. El-Deiry,
K. W. Kinzler, and B. Vogelstein.
1994.
Sequence-specific transcriptional activation is essential for growth suppression by p53.
Proc. Natl. Acad. Sci. USA
91:1998-2002[Abstract/Free Full Text].
|
| 19.
|
Reynisdottir, I.,
K. Polyak,
A. Iavarone, and J. Massague.
1995.
Kip/cip and ink4 cdk inhibitors cooperate to induce cell cycle arrest in response to TGF- .
Genes Dev.
9:1831-1845[Abstract/Free Full Text].
|
| 20.
|
Ruaro, E. M.,
L. Collavin,
G. Del Sal,
R. Haffner,
M. Oren,
A. J. Levine, and C. Schneider.
1997.
A proline-rich motif in p53 is required for transactivation independent growth arrest as induced by Gas1.
Proc. Natl. Acad. Sci. USA
94:4675-4680[Abstract/Free Full Text].
|
| 21.
|
Samad, A., and R. B. Carroll.
1991.
The tumor suppressor p53 is bound to RNA by a stable covalent linkage.
Mol. Cell. Biol.
11:1598-1606[Abstract/Free Full Text].
|
| 22.
|
Shirodkar, S.,
M. Ewen,
J. A. DeCaprio,
J. Morgan,
D. M. Livingston, and T. Chittenden.
1992.
The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner.
Cell
68:157-166[CrossRef][Medline].
|
| 23.
|
Taylor, S. J., and D. Shalloway.
1994.
An RNA-binding protein associated with src through its SH2 and SH3 domains in mitosis.
Nature
368:867-871[CrossRef][Medline].
|
| 24.
|
Walker, K. K., and A. J. Levine.
1996.
Identification of a novel p53 functional domain that is necessary for efficient growth suppression.
Proc. Natl. Acad. Sci. USA
93:15335-15340[Abstract/Free Full Text].
|
| 25.
|
Weng, Z.,
S. M. Thomas,
R. J. Rickles,
J. A. Taylor,
A. W. Brauer,
C. Seidel-Dugan,
W. M. Michael,
G. Dreyfuss, and J. S. Brugge.
1994.
Identification of Src, Fyn, and Lyn SH3-binding proteins: implications for a function of SH3 domains.
Mol. Cell. Biol.
14:4509-4521[Abstract/Free Full Text].
|
| 26.
|
Wu, L.,
J. H. Bayle,
B. Elenbaas,
N. P. Pavletich, and A. J. Levine.
1995.
Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids.
Mol. Cell. Biol.
15:497-504[Abstract].
|
| 27.
|
Zapp, M. L.,
S. Stern, and M. R. Green.
1993.
Small molecules that selectively block RNA binding of HIV-1 rev protein inhibit rev function and viral production.
Cell
74:969-978[CrossRef][Medline].
|
Molecular and Cellular Biology, November 2000, p. 8420-8431, Vol. 20, No. 22
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Horvilleur, E., Bauer, M., Goldschneider, D., Mergui, X., de La Motte, A., Benard, J., Douc-Rasy, S., Cappellen, D.
(2008). p73{alpha} isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells. Nucleic Acids Res
36: 4222-4232
[Abstract]
[Full Text]
-
Riley, K. J.-L., Maher, L. J. III
(2007). p53 RNA interactions: New clues in an old mystery. RNA
13: 1825-1833
[Abstract]
[Full Text]
-
Nie, M., Htun, H.
(2006). Different modes and potencies of translational repression by sequence-specific RNA-protein interaction at the 5'-UTR. Nucleic Acids Res
34: 5528-5540
[Abstract]
[Full Text]
-
RILEY, K. J.-L., CASSIDAY, L. A., KUMAR, A., MAHER, L. J. III
(2006). Recognition of RNA by the p53 tumor suppressor protein in the yeast three-hybrid system.. RNA
12: 620-630
[Abstract]
[Full Text]
-
Xi, Y., Shalgi, R., Fodstad, O., Pilpel, Y., Ju, J.
(2006). Differentially Regulated Micro-RNAs and Actively Translated Messenger RNA Transcripts by Tumor Suppressor p53 in Colon Cancer.. Clin. Cancer Res.
12: 2014-2024
[Abstract]
[Full Text]
-
Meng, Z., King, P. H., Nabors, L. B., Jackson, N. L., Chen, C.-Y., Emanuel, P. D., Blume, S. W.
(2005). The ELAV RNA-stability factor HuR binds the 5'-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translation. Nucleic Acids Res
33: 2962-2979
[Abstract]
[Full Text]
-
Fukuda, T., Ashizuka, M., Nakamura, T., Shibahara, K., Maeda, K., Izumi, H., Kohno, K., Kuwano, M., Uchiumi, T.
(2004). Characterization of the 5'-untranslated region of YB-1 mRNA and autoregulation of translation by YB-1 protein. Nucleic Acids Res
32: 611-622
[Abstract]
[Full Text]
-
Itoh, T., O'Shea, C., Linn, S.
(2003). Impaired Regulation of Tumor Suppressor p53 Caused by Mutations in the Xeroderma Pigmentosum DDB2 Gene: Mutual Regulatory Interactions between p48DDB2 and p53. Mol. Cell. Biol.
23: 7540-7553
[Abstract]
[Full Text]
-
Strudwick, S., Carastro, L. M., Stagg, T., Lazarus, P.
(2003). Differential Transcription-Coupled Translational Inhibition of Human p53 Expression: A Potentially Important Mechanism of Regulating p53 Expression in Normal versus Tumor Tissue. Mol Cancer Res
1: 463-474
[Abstract]
[Full Text]
-
Cassiday, L. A., Maher III, L. J.
(2002). Having it both ways: transcription factors that bind DNA and RNA. Nucleic Acids Res
30: 4118-4126
[Abstract]
[Full Text]
-
Borden, K. L. B.
(2002). Pondering the Promyelocytic Leukemia Protein (PML) Puzzle: Possible Functions for PML Nuclear Bodies. Mol. Cell. Biol.
22: 5259-5269
[Full Text]
-
Adilakshmi, T., Laine, R. O.
(2002). Ribosomal Protein S25 mRNA Partners with MTF-1 and La to Provide a p53-mediated Mechanism for Survival or Death. J. Biol. Chem.
277: 4147-4151
[Abstract]
[Full Text]